TOYOCHEM and Dite sign an agreement to build a partnership on pharmaceuticals

This page has been translated using AI.

artience group TOYOCHEM CO., LTD. (President and Representative Director Yasushi Ariyoshi, Chuo-ku, Tokyo) and Daito Co., Ltd. (President and Representative Director and CEO Hiroshi Matsumori, Toyama City, Toyama Prefecture) are pleased to announce that they have signed an agreement to build a partnership on April 7.

From left to right, Hiroshi Matsumori, President and Representative Director and CEO of Dite, and Yasushi Ariyoshi TOYOCHEM President and Representative Director

Overview
Under the "Agreement to Build a Partnership" signed by TOYOCHEM and Dite, the two companies have agreed to start consideration and activities to establish a business and business alliance relationship centered on the area of drug development related to dermal absorption, utilizing each other's expertise and mutually utilizing each other's expertise.

About the contents of the agreement
This agreement is based on the premise that TOYOCHEM will leverage its strengths in formulation development and production system for transdermal formulations, and Dite's knowledge of clinical trials, regulatory regulations, quality assurance, etc. in Japan and abroad, as well as a high-quality and stable API manufacturing system, with a view to the global domain. The two agreed to actively begin discussions toward a business that develops, manufactures, and sells high-value-added formulations in collaboration with each other.

About TOYOCHEM 's Transdermal Formulation Business

TOYOCHEM is the core of artience group 's polymer and coatings-related businesses, focusing on the medical and healthcare fields, and is committed to the development of transdermal patches, pressure sensitive adhesives, and biocompatible polymers.
In the pharmaceutical field, we contribute to improving the quality of life of patients through the development and manufacture of transdermal patches (TDDS formulations). transdermal patches, which continuously administers active ingredients through the skin by applying it to the body, offers benefits that other dosage forms do not have, such as ease of medication, stable drug administration, and visibility of medication status.
By combining formulation design, polymer development, and coating processing technologies, we aim to realize the "safe and skin-friendly transdermal formulations" that medical settings and patients demand. To achieve this, we have transferred our manufacturing and R&D bases to the Moriyama Plant in Shiga Prefecture to strengthen our structure as a CDMO company. In addition, we are accelerating the development of next-generation transdermal formulations by promoting open innovation through strengthening collaboration with academia and external partners.

transdermal patches (TDDS Formulation)
https://www. artience group.com/ja/products/medical-bio/transdermal-medicine/

About Dite Corporation

Dite (Headquarters: Toyama Prefecture) is a pharmaceutical company that engages in the two pillars of pharmaceutical raw materials, APIs and formulations, from R&D to manufacturing, on a global scale.　Since its founding in 1942, we have manufactured and sold APIs and formulations for medical and over-the-counter use, and have achieved business results with more than 90% of pharmaceutical companies in Japan. For more information, please refer to the website (https://www.daitonet.co.jp/).